Home » Serono and Syntonix Sign Agreement to Develop Therapy
Serono and Syntonix Sign Agreement to Develop Therapy
March 31, 2005
Serono and Syntonix Pharmaceuticals Inc. announced that they have entered into an agreement under which Serono has licensed worldwide exclusive rights to Syntonix' Transceptor and Synfusion technologies for the development and commercialization of interferon-beta:Fc products. Syntonix' technologies may enable the development of an interferon-beta therapy for multiple sclerosis (MS) that can be administered by inhalation. It has been demonstrated that certain Fc constructs can facilitate transport of therapeutic proteins across the lung epithelium through neonatal Fc receptor-mediated uptake.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19545320&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct